Isavuconazole

Isavuconazole (BAL-4815) is a triazole proagent with antifungal activity against yeasts, molds, and dimorphic fungi. Isavuconazole inhibits ergosterol biosynthesis and results in the disruption of fungal membrane structure and function. Isavuconazole is a moderate inhibitor of CYP3A4.

Product Specifications

CAS Number

[241479-67-4]

Product Name Alternative

BAL-4815; RO-0094815

UNSPSC

12352005

Hazard Statement

H361

Target

Antibiotic; Cytochrome P450; Fungal

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/Isavuconazole.html

Purity

99.99

Solubility

DMSO : ≥ 50 mg/mL

Smiles

FC1=CC=C(F)C=C1[C@](CN2C=NC=N2)(O)[C@@H](C)C3=NC(C4=CC=C(C#N)C=C4)=CS3

Molecular Formula

C22H17F2N5OS

Molecular Weight

437.47

Precautions

H361

References & Citations

[1]Seifert H, et al. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother. 2007 May;51 (5) :1818-21.|[2]Steinmann J, et al. In Vitro Activity of Isavuconazole against Rasamsonia Species. Antimicrob Agents Chemother. 2016 Oct 21;60 (11) :6890-6891.|[3]Donnelley MA, et al. Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections. Infect Drug Resist. 2016 Jun 2;9:79-86.|[4]Box H, et al. Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis. Antimicrob Agents Chemother. 2015 Oct 26;60 (1) :278-87.|[5]Livermore J, et al. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol. 2012 Jun;8 (6) :759-65.